Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Subgen AI AB is a Swedish biotechnology company specializing in the development and commercialization of diagnostic tests that monitor and optimize the dosage of biological drugs. Established in 2019 and based in Lund, Sweden, the company offers innovative testing platforms geared toward oral health, therapeutic drug monitoring, and infectious disease detection. Key technologies include Veritope, designed to enhance dosing accuracy for biological therapeutics, and the MagniaReader platform utilized in both research and veterinary settings. Formerly known as Magnasense AB until its rebranding in November 2025, Subgen AI AB serves a critical role in improving personalized medicine through advanced diagnostic tools, contributing to more effective and tailored patient care in the pharmaceutical and healthcare industries.
kr 0.00
kr 0.00 (-5.26%)
EOD Jun 26, 2026 · Twelve Data
The business is unprofitable at the operating level (-15.18% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 0.3%, essentially flat. Margins also contracted 34.9pp. This is a business that needs a catalyst.
ROIC dropped from 56.33% to -9.33%, capital efficiency is deteriorating. Negative free cash flow of -kr 50M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 211M
▲ +0.3% YoY
Net Income (TTM)
-kr 49M
▼ -289.0% YoY
Op. Margin
-15.72%
▼ -34.9pp YoY
ROIC
-9.33%
▼ -65.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 22M
▼ -5.4% YoY
Op. Cash Flow (TTM)
kr 1M
▼ -124.9% YoY
Net Debt
kr 33M
Cash & Equiv.
kr 30M
Continue Research
Subgen AI AB (SUBGEN.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Subgen AI AB scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Subgen AI AB scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -15.7% operating margin and a -9.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SUBGEN.XSTO's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.